PsaA Peptide Adjuvants Reduce Antigen Dose and Toxicity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current vaccines face challenges such as high costs, adverse side effects, instability, and the need for large amounts of antigenic material, particularly in developing countries, where affordability and accessibility are concerns, and there is a need for safer and more effective adjuvants to enhance immune responses.
Innovation Solution
Incorporating peptides derived from pneumococcal surface adhesin A (PsaA) protein into vaccine formulations to reduce the amount of antigenic material required for an effective immune response, using sequences of at least 12 contiguous amino acids, which can be combined with antigenic material and a pharmaceutically acceptable carrier for administration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional adjuvants (e.g., aluminum salts, oil emulsions) are used to enhance immune response, then the immune response is improved, but adverse side effects and toxicity increase
Solution Approach 1:
The patent changes the chemical parameters of adjuvants by using peptides with specific amino acid sequences (e.g., sequences containing hydrophobic regions and specific motifs) instead of traditional aluminum salts or oil emulsions. This parameter change maintains immune response efficacy while reducing toxicity and adverse side effects, as the peptide adjuvants are biocompatible and can be precisely engineered for desired properties.
Solution Approach 2:
The patent employs composite adjuvant formulations consisting of multiple peptide components with different functions (e.g., immunostimulatory peptides, adhesion-promoting peptides, and stabilizing peptides). These composite peptide-based adjuvants work synergistically to enhance immune response while minimizing adverse effects, providing a safer alternative to traditional single-component adjuvants.
2Reliability
If larger amounts of antigenic material are used per dose, then immune response is improved, but vaccine cost and manufacturing complexity increase
Solution Approach 1:
The patent introduces peptide adjuvants as intermediary substances that mediate between the antigenic material and the immune system. These peptides enhance the immunogenicity of the antigen, allowing for reduced antigen doses while maintaining effective immune responses. This intermediary action reduces the amount of expensive antigenic material needed per dose, lowering manufacturing costs and simplifying production.
3Quantity of substance
If traditional adjuvants are used to reduce antigen dose, then the amount of antigenic material is reduced, but safety and stability concerns arise
Solution Approach 1:
The patent employs peptide adjuvants that are biodegradable and can be safely metabolized by the body, unlike persistent traditional adjuvants. These peptide components are designed to be temporarily active during the immune response initiation phase and then naturally degraded, providing safety advantages while effectively reducing antigen dose requirements.
Solution Approach 2:
The patent optimizes peptide stability parameters through specific amino acid sequence design, including incorporation of disulfide bonds, hydrophobic cores, and resistance to proteolytic degradation. These parameter changes ensure the peptide adjuvants remain stable during storage and administration while maintaining safety profiles superior to traditional adjuvants.
Data Source
AI summary
The present invention is directed to methods for administering antigenic material to a patient as a vaccine against an infection comprising providing both an antigenic material specific to the desired immunological response desired plus an adjuvant comprised of a peptide of a sequence derived from the sequence of pneumococcal surface adhesin A protein (PsaA). Preferably the peptide comprises a sequences derived from one or more sequences of PsaA that contain the epitope regions or contiguous amino acids of SEQ ID NOs 1 or 2. The invention is also directed to vaccine compositions containing adjuvant of the invention and also adjuvant compositions of the invention.